Value of Adding T2 Mapping Routine MRI in Assessment of Knee Articular Cartilage Early Osteoarthritis (T2 mapping OS)

December 30, 2025 updated by: Shrouk Mohamed Gad, Assiut University

Value of Adding T2mapping Sequence to Routine MRI Protocol in Assessment of Knee Articular Cartilage in Early Osteoarthritis

This work aims at elucidating the role of MRI complementary T2 mapping in assessment of the articular knee cartilage for improving sensitivity of detection of early stage of osteoarthritis

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Detailed Description

Osteoarthritis (OA) is one of the most common degenerative joint diseases, affecting more than 500 million people worldwide (1), causing joint pain and stiffness, and negatively affecting quality of life . The knee is the most commonly affected joint, followed by the hand and hip (1).

It is important clinically to diagnose osteoarthritis in its early stages to prevent its inevitable progression (2) Routine MR imaging sequences used in the identification of knee osteoarthritis can assess articular cartilage morphology, but despite its accuracy for identifying deep hyaline cartilage defects which are considered irreversible cartilage degeneration with limited treatment options, it lacks sufficient sensitivity for early cartilage changes and low-grade chondral lesions which are the reversible stages for the potential alteration of the osteoarthritis progression(2).

T2 mapping of hyaline cartilage is an imaging technique for the qualitative and quantitative detection of the cartilage providing convincing color mapping and quantitative detection of the cartilage mainly regarding architecture and changes in water content, proteoglycan, and collagen matrix ultra-structure associated with early cartilage degeneration(3).

T2 mapping is a time constant describing the rate at which energy transfer occurs between water protons in a magnetic field (spin-spin interactions), leading to signal dephasing. In normal healthy articular cartilage, water protons are largely bound in place by a well-organized matrix of collagen fibers, allowing for rapid dephasing, and therefore low T2 values are seen(4). However, in osteoarthritic articular cartilage, the collagen fibers become disorganized, and there are more mobile water protons, resulting in high T2 values. (4).

Study Type

Observational

Enrollment (Estimated)

70

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

any patient with knee pain with no history of previous lustrophobiaoperation and has no metallic element inside his body with no ca

Description

Inclusion Criteria:

  • patients with clinical evidence of osteoarthritis

Exclusion Criteria:

  • • contraindications for MRI such as claustrophobia, heart pacemaker and ferromagnetic implants

    • patients in which the misaligned images or distortions due to motion artifacts made the interpretation of the MRI unreliable.
    • Patients with previous knee operation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
This work aims at elucidating the role of MRI complementary T2 mapping to measure the changes in T2 relaxation time of the articular knee cartilage in healthy group which there number will be 28 and pateints with early osteoarthritis there number 28
Time Frame: baseline
to detect the value of adding T2 mapping to routine MRI in assessment of the articular cartilage in knee osteoarthritis
baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
This work aims at quantitive stratification of osteoarthrtic changes and its impact on treatement
Time Frame: baseline
to detect the value of adding T2 mapping to routine MRI in assessment of knee articular cartilage in knee osteoarthritis
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Abeer Houssein Ali, prof.dr, Assiut University
  • Study Director: Ahmed Moustafa Mohamed, prof, Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2026

Primary Completion (Estimated)

January 12, 2027

Study Completion (Estimated)

February 1, 2027

Study Registration Dates

First Submitted

December 16, 2025

First Submitted That Met QC Criteria

December 30, 2025

First Posted (Actual)

January 5, 2026

Study Record Updates

Last Update Posted (Actual)

January 5, 2026

Last Update Submitted That Met QC Criteria

December 30, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • T2 mapping in osteoarthritis

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe